Asthma is a complex and heterogeneous disorder characterized by chronic airway inflammation with variable airflow obstruction that affects people of any age. It is associated with an earlier decline of lung function over time and, in some cases, reduced lung function growth during childhood/adolescence ([@bib1], [@bib2]). Antiinflammatory corticosteroids are the mainstay of asthma treatment from infancy to senescence, often combined with long-acting β-agonists in patients older than 6 years of age ([@bib3]). In most subjects, corticosteroids allow clinical control of asthma (symptomatic treatment) and are also effective as disease-modifying therapy, inhibiting lung function decline in both children and adults ([@bib4], [@bib5]).

However, a clinically relevant proportion of individuals with asthma do not respond to corticosteroid treatment, even when administered at high doses. Severe steroid-resistant asthma affects 5--10% of adult patients, who disproportionately account for 50--80% of all asthma-associated healthcare costs ([@bib6]). The epidemiology and prevalence of severe steroid-resistant asthma in children are unclear ([@bib7]). In adults, severe asthma is classified based on the inflammatory profile as T2 high and T2 low. The latter is often characterized by neutrophilic inflammation, an indication of steroid resistance.

The molecular mechanisms leading to corticosteroid resistance are various and only partially understood ([@bib6]). Their identification could pave the way for new treatment targets in asthma. Even better, unraveling the risk factors associated with the development of corticosteroid resistance over time could allow early targeted interventions and the implementation of preventive precision medicine ("precision prevention"). Complex interactions between genetic and environmental factors regulate corticosteroid resistance. The genetic factors include microRNAs (miRNAs), which are are small noncoding RNAs that intervene in gene expression regulation during inflammatory and immune responses, and are recognized as possible genetic modulators of steroid sensitivity in asthma ([@bib6]).

In this issue of the *Journal*, Gomez and colleagues (pp. [51--64](10.1164/rccm.201912-2360OC)) and Li and colleagues (pp. [65--72](10.1164/rccm.201907-1454OC)) provide additional data about the role of miRNAs in corticosteroid-resistant asthma in children and neutrophilic adults, respectively ([@bib8], [@bib9]).

Li and coworkers identified seven circulating miRNAs associated with treatment response, quantified as the change in FEV~1~% predicted after 4 years, in a cohort of nearly 500 children with asthma who were selected from the CAMP (Childhood Asthma Management Program) study and were receiving either budesonide or placebo. Based on an adjusted analysis, the miRNAs with the greatest effects on treatment response were miR-155-5p and miR-532-5p. These two miRNAs had different effects: increasing levels of circulating miR-155-5p were associated with an increased response to budesonide, whereas the opposite was true for miR-532-5p. In an attempt to validate these biological effects, the authors intriguingly observed that miR-155-5p inhibited, rather than enhanced, the transrepressive effects of corticosteroids on IL-1β expression in lung epithelial cells *in vitro*. Also, circulating miR-155-5p levels predicted treatment response with an area under the receiver operating characteristic curve of 0.85. However, the prediction data were obtained using only the (unspecified) highest versus lowest quartiles of response, leaving a large gray zone. In the absence of a complete analysis, we wonder whether including the highest versus lowest quartiles of miRNA levels in the same model could have been more informative in terms of prediction? With this in mind, it is still encouraging to find that long-term treatment response can be predicted as early as in the first decade of life with the use of circulating biomarkers, at least in a subpopulation of patients selected *a posteriori*. The opposite effects observed in intracellular versus extracellular compartments for the same miRNA are intriguing and raise new questions. It would be informative to reproduce the experimental approach using primary cells from individuals with asthma and control subjects, and using stimuli more "typical" of the asthmatic response in children, such as T2 cytokines. Similar approaches should also be applied to other structural and immune cell types that are more likely involved in the asthmatic response to identify the targets of miRNA-155-5p.

Gomez and colleagues used RNA sequencing and complex bioinformatics to match miRNA networks with clinical phenotypes of the disease and with specific patterns of mRNA expression in sputum cells from 62 subjects with mild-to-severe asthma and 9 control subjects. They found a miRNA network (the "nely" network) associated with sputum neutrophilia and lymphocytosis, reduced FEV1% predicted and quality of life, and increased hospitalizations in the previous year. Among the 12 nely miRNAs identified, the one that most closely correlated with these clinical aspects was miR-223-3p, which the authors showed to be expressed in neutrophils and lymphocytes. However, they did not exclude the possibility that other cell types express this miRNA. Clustering the patients in two groups based on their expression of nely miRNAs revealed that, with similar ICS doses, subjects with asthma and high nely miRNA expression had reduced FEV~1~% predicted both before and after bronchodilation. Lastly, the authors identified patterns of mRNA expression linked to the T-helper cell type 17 (Th17) response, TLR, and unfolded protein response/endoplasmic reticulum stress associated with the nely miRNA network. Overall, these data confirm previous findings and suggest that miRNA could play an important role in neutrophil biology and neutrophil--lymphocyte signaling. Severe steroid-resistant asthma has been associated clinically with increased sputum and bronchial neutrophilia, high exacerbation rates, and decreased quality of life ([@bib10]--[@bib12]). An increased expression of miR-223-3p has already been described in neutrophilic asthma ([@bib13]). Also, the Th17 and unfolded protein responses are increasingly recognized as mechanisms of corticosteroid resistance in asthma ([@bib14], [@bib15]). Several questions remain to be answered. Is there a role for such miRNA in disease pathobiology, or is it simply a marker of neutrophilia? Do circulating neutrophils express the same miRNA pattern? Can we prove biologically what has been inferred bioinformatically? These are all questions that deserve to be answered in the future.

More research is clearly warranted to clarify the role of miRNAs in asthma, and the current data are too limited to speculate about their possible use in clinical practice. Although the novel findings of these studies provide evidence in support of the potential use of miRNAs in disease subendotyping and asthma management, they need to be confirmed in other cohorts, and many mechanistical issues remain to be addressed. The dichotomous function observed intracellularly versus extracellularly for some miRNAs, along with their potential pleiotropic role in physiological processes, raises doubts concerning their use as drug targets at present.
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